共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | WJH 6^(th) Anniversary Special Issues(7): Nonalcoholic fatty liver disease Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease affects approximately one-third of the population worldwide, and its incidence continues to increase with the increasing prevalence of other metabolic disorders such as type 2 diabetes. As non-alcoholic fatty liver disease can progress to liver cirrhosis, its treatment is attracting greater attention. The pathogenesis of non-alcoholic fatty liver disease is closely associated with insulin resistance and dyslipidemia, especially hypertriglyceridemia. Increased serum levels of free fatty acid and glucose can cause oxidative stress in the liver and peripheral tissue, leading to ectopic fat accumulation, especially in the liver. In this review, we summarize the mechanism underlying the progression of hepatic steatosis to steatohepatitis and cirrhosis. We also discuss established drugs that are already being used to treat non-alcoholic fatty liver disease, in addition to newly discovered agents, with respect to their mechanisms of drug action, focusing mainly on hepatic insulin resistance. As well, we review clinical data that demonstrate the efficacy of these drugs, together with improvements in biochemical or histological parameters. | Hye-jin Yoon Bong Soo Cha | 2014 | World Journal of Hepatology2014，6，11： | 20 |
| 2 | Insulin sensitizers for the treatment of non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD) is the leading cause of liver disease in the Western world and is closely associated with metabolic syndrome,which includes hypertension,central obesity,dyslipidemia and insulin resistance.NAFLD includes a wide spectrum of liver alterations,ranging from simple hepatic steatosis to variable degrees of fibrosis,cirrhosis and even hepatocellular carcinoma.Although the etiology and progression of the disorder remain poorly understood,insulin resistance is considered to play a pivotal role in the pathogenesis.Insulin sensitizers such as biguanides,thiazolidinediones(TZDs),glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors have been studied as therapeutic approaches for NAFLD in recent years.Metformin improves insulin sensitivity and serum alanine transaminase and aspartate transaminase(ALT/AST) levels in the majority of subjects; however,it has no significant effect on liver histology.TZDs improve insulin sensitivity,serum ALT/ AST levels and histology in some cases,but there are some concerns about the safety of long-term therapy.Selection of appropriate patients for avoiding side effects and the treatment of underlying disease are themain points.These drugs are the best choice for the treatment of NAFLD in patients with type 2 DM who are also candidates for treatment with an insulin sensitizer.The present review provides an overview of insulin sensitizers in the treatment of NAFLD. | Zeynel Abidin Ozturk Abdurrahman Kadayifci | 2014 | World Journal of Hepatology2014，6，4： | 14 |
您所在的机构暂未开通此部分的功能，请联系管理员